Watchlist Signal

Tacrolimus (ARM with Methotrexate)

Tacrolimus (ARM with Methotrexate) is flagged as watchlist signal because public records show operational burden. This is a public-data monitoring signal, not a conclusion about clinical failure, regulatory noncompliance, or sponsor intent.

Program overview

Context

Indication: Acute Leukemia

Mechanism: Unknown

Modality: Unknown

Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Scores

Risk-signal summary

Registry: 0/5

Timeline: 1/5

Recruitment burden: 2/5

Results availability: 0/5

Program risk: 2/5

Evidence

Public links

https://clinicaltrials.gov/study/NCT02208037

Linked trials

Trial-level signal details

TrialStatusTimelineResultsBurden
NCT02208037Low Signal (COMPLETED)stale_update_signalLow Signallarge_enrollment_target_signal | rare_population_signal